Silence Therapeutics (SLNCF) 1.5000 $SLNCF
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 13.58 (+0.17), PFE: 35.35 (+0.26), OMER: 11.19 (-0.07), ICPT: 168.04 (+0.97), ABBV: 66.00 (-0.17), IONS: 34.26 (+0.55), NVS: 81.13 (-0.23)
Acute Lung Injury - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 5:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mlvm2/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Altor BioScience Corporation - Apeptico Forschung und Entwicklung GmbH - Bayer AG - BioMarck Pharmaceuticals, Ltd. - Carolus Therapeutics, Inc. - CompleGen, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Histocell S.L. - Navigen Pharmaceuticals, Inc. - Noxxon Pharma AG - Quark Pharmaceuticals, Inc. - S-Evans Biosciences, Inc. - Silence Therapeutics Plc - Stemedica Cell Technologies, Inc. - Xiber Science GmbH Key Topics Covered: - Introduction - Acute Lung Injury Overview - Therapeutics Development - Pipeline Products for Acute Lung Injury - Overview - Pipeline Products for Acute Lung Injury - Comparative Analysis - Acute Lung Injury - Therapeutics under Development by Companies - Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes - Acute Lung Injury - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lung Injury - Products under Development by Companies - Acute Lung Injury - Products under Investigation by Universities/Institutes - Acute Lung Injury - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/2m...ung_injury
GSK: 44.38 (-0.03)
Silence Therapeutics Plc Industry - Product Pipeline Review - 2015
M2 - Wed Dec 23, 4:02AM CST
Acute Market Reports's, 'Silence Therapeutics plc - Product Pipeline Review - 2015', provides an overview of the Silence Therapeutics plc's pharmaceutical research and development focus.
Liver Failure Pipeline Review, H2 2015 - Analysis, Trends & Forecasts
M2 - Thu Dec 17, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8578pm/liver_failure) has announced the addition of the "Liver Failure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Liver Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics Companies Mentioned: - Alfact Innovation - Cell2B S.A. - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Immune Pharmaceuticals Inc. - Silence Therapeutics Plc - Ventria Bioscience For more information visit http://www.researchandmarkets.com/research/85...er_failure
CNAT: 1.97 (+0.04), IMNP: 0.38 (unch)
Acute Respiratory Distress Syndrome Pipeline Report 2015 - 12 Companies & 23 Drug Profiles
M2 - Tue Dec 15, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/ct5nmx/acute_respiratory) has announced the addition of the "Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Athersys, Inc. - BioMarck Pharmaceuticals, Ltd. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - GlaxoSmithKline Plc - Histocell S.L. - Myelo Therapeutics GmbH - Phylogica Limited - Serendex Pharmaceuticals A/S - Silence Therapeutics Plc - Therabron Therapeutics, Inc. Drug Profiles - ALT-836 - BIO-10901 - CG-367 - Cyndacel-M - GSK-2586881 - GSK-2862277 - interferon beta-1a - molgramostim - Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - MultiStem - Myelo-001 - Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - PYC-35 - PYC-36 - PYC-38 - PYC-98 - Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - S-1229 - SAN-101 - Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Stem Cell Therapy for Inflammatory Lung Diseases - Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome For more information visit http://www.researchandmarkets.com/research/ct...espiratory
GSK: 44.38 (-0.03), ATHX: 1.98 (unch)
Global Pulmonary Arterial Hypertension Pipeline Report H2 2015
M2 - Thu Dec 10, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7nnftw/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bial - Portela & Ca, S.A. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Insmed Incorporated - Lacer, S.A. - LTT Bio-Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - miRagen Therapeutics, Inc. - Nippon Shinyaku Co., Ltd. - Novartis AG - Peloton Therapeutics, Inc. - PharmaIN Corporation - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Pulmokine, Inc. - Reata Pharmaceuticals, Inc. - Respira Therapeutics, Inc. - Sagene Pharmaceuticals, Inc. - Silence Therapeutics Plc - Sinoxa Pharma GmbH - SteadyMed Therapeutics, Inc. - Suda Ltd - Toray Industries, Inc. For more information visit http://www.researchandmarkets.com/research/7nnftw/pulmonary
CYTK: 12.27 (+0.14), INSM: 13.58 (+0.17), PSTI: 1.72 (+0.04), LLY: 79.50 (-0.07), CLSN: 1.32 (unch), ASND: 18.45 (unch), GILD: 82.02 (+0.55), ARNA: 1.68 (unch), NVS: 81.13 (-0.23)
PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis
M2 - Fri Sep 25, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nl5w7p/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report to their offering. "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, we provide an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics. Key Questions Answered - What are the drivers of the RNAi therapy field? - Who are the leading companies involved in the development of RNAi therapies? - What are the major trends in RNAi clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the antisense/RNAi therapy field? Scope - This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments - Investment examined from both industry and financial communities - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activities - Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Report Scope 2.2 Companies Mentioned 2.3 Related Reports 3 Antisense RNAi Therapy Overview 3.1 What is Antisense Therapy? 3.2 The Second Era of RNAi 4 Clinical Trials 4.1 Overview 4.2 Company 4.3 Phase of Development 4.4 Therapy Area 4.5 Indication 4.6 Investigators 5 Company Analysis 5.1 Overview 5.2 Pipeline Profiles 6 Deals Landscape 6.1 Overview 6.2 Deal Type 7 Strategic Outlook 8 Appendix Companies Featured: - Alnylam Pharmaceuticals - Antisense Therapeutics - Arrowhead Research Corporation - AuraSense Therapeutics - BioMarin Pharmaceuticals - Dicerna Pharmaceuticals - Gene Signal International SA - Idera Pharmaceuticals - InDex Pharmaceuticals AB - Isarna Therapeutics GmbH - Isis Pharmaceuticals - Miragen Therapeutics - Mirna Therapeutics - Moderna Therapeutics - Mologen AG - Oncogenex Pharmaceuticals - Quark Pharmaceuticals - Regulus Therapeutics - RXi Pharmaceuticals - Sarepta Therapeutics - Silence Therapeutics Plc - Sirnaomics - Sterna Biologicals GmbH - Sylentis SA - Tekmira (Arbutus) Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/nl...armasphere
ISIS: 57.56 (-0.28), IDRA: 2.04 (+0.09), DRNA: 3.68 (unch), ARWR: 7.52 (-0.56), SRPT: 27.99 (+1.75), RGLS: 3.49 (+0.05), MIRN: 3.12 (+0.02)
Acute Lung Injury Pipeline Review, H1 2015 - 15 Companies & 37 Drug Profiles
M2 - Tue Jul 28, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w2nt98/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Apeptico Forschung und Entwicklung GmbH - BioMarck Pharmaceuticals, Ltd. - Carolus Therapeutics, Inc. - CompleGen, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Histocell S.L. - Navigen Pharmaceuticals, Inc. - Noxxon Pharma AG - S-Evans Biosciences, Inc. - Silence Therapeutics Plc - Stemedica Cell Technologies, Inc. - Therametrics holding AG - Xiber Science GmbH Drug Profiles - ALT-836 - AP-301 - Atu-111 - Atu-112 - BC-1215 - BIO-10901 - CGX-1037 - CT-2009 - DasKloster-0141-01 - DasKloster-1000-04 - Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - GSK-2586881 - GSK-2862277 - HC-016 - LTI-02 - Mesenchymal Stem Cells - MG-53 - Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - NOXD-19 - P- BEFizumab - Peptide to Activate PAI-1 for Acute Lung Injury - Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - S-1229 - Small Molecules for Inflammatory Diseases and Sepsis - Small Molecules to Inhibit Arf6 for Multiple Diseases - Stem Cell Therapy for Acute Lung Injury - Stem Cell Therapy for Inflammatory Lung Diseases - Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Stromal Cell Therapy for Acute Lung Injury - Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury For more information visit http://www.researchandmarkets.com/research/w2...ung_injury
GSK: 44.38 (-0.03)
Silence Therapeutics plc - Product Pipeline Review - 2014
M2 - Wed Jun 17, 4:39AM CDT
Global Sepsis Pipeline Review 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch9d7/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adrenomed AG - Altor BioScience Corporation - Am-Pharma B.V. - Arch Biopartners, Inc. - Asahi Kasei Pharma Corp. - Baxter International Inc. - Biomedica Management Corporation - Chiesi Farmaceutici SpA - Chiome Bioscience, Inc. - Cilian AG - Cognosci, Inc. - Diomune S.L - Endacea, Inc. - Evec, Inc. - Huons Co., Ltd. - Immune Response BioPharma, Inc. - ImmunNovative Developments SL - InflaRx GmbH - Integrated BioTherapeutics, Inc. - ISU ABXIS Co.,Ltd. - Lead Discovery Center GmbH - MSM Protein Technologies, Inc. - Navigen Pharmaceuticals, Inc. - Novadiscovery SAS - Noxxon Pharma AG - Ocata Therapeutics, Inc. - OncoImmune, Inc. - Opsona Therapeutics Ltd. - ProThera Biologics, LLC. - Silence Therapeutics plc - Stemedica Cell Technologies, Inc. - Syntiron LLC - Takeda Pharmaceutical Company Limited - TiGenix NV - XImmune AB For more information visit http://www.researchandmarkets.com/research/gc...s_pipeline
OCAT: 8.47 (+0.01), BAX: 47.75 (-0.23), ACH: 9.15 (+0.10)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 82.02 (+0.55), PFE: 35.36 (+0.27), GALT: 2.01 (+0.02), FGEN: 19.43 (+0.32), CELGZ: 1.26 (+0.11)
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 82.02 (+0.55), ICPT: 168.04 (+0.97), TBRA: 4.76 (-0.09), CELGZ: 1.26 (+0.11)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 11.19 (-0.07)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 2.96 (-0.01), AMGN: 174.04 (-0.36), RGLS: 3.49 (+0.05), LLY: 79.50 (-0.07), GSK: 44.38 (-0.03), PVCT: 0.25 (unch), CANF: 2.41 (+0.04), DCTH: 3.99 (-0.05), NVS: 81.12 (-0.24), XLRN: 31.66 (+0.75)
Global RNA Based Therapeutics Market 2014-2020: Market to Grow at CAGR of 28% and Reach $1.2 Billion in 2020
M2 - Wed Oct 22, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4cwd5m/global_rna_based) has announced the addition of the "Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The RNA Based Therapeutics Market would reach $1.2 billion by 2020 registering a CAGR of 28.4% during 2014 - 2020 Due to its ability to render targeted solutions for chronic diseases such as cancer, AIDS, rare genetic disorders, and certain cardiovascular conditions, RNA based therapeutics is expected to significantly impact the global pharmaceutical industry. The large scale funding from public and private sector, growing interest of pharmaceuticals and biotech giants for developing novel delivery technology, and anticipated saving in healthcare expenditure are propelling the growth of RNA therapeutics market. Moreover, the platform technologies such as RNAi and antisense have enabled researchers to accelerate their research activities by defining gene sequences for chronic diseases. Companies have widened the research focus on RNA based drug as well, which has fueled the growth of the overall RNA therapeutics market.Pharmaceutical companies have identified the RNA therapeutics for variety of chronic diseases and are also exploring the potential of RNA technology for diagnostic purposes. The RNA based therapeutics market, in the near future is likely to witness a substantial level of momentum due to government funding and programs aimed at commercialization of these drugs. The government of United States, through its National Institute of Health (NIH), provides funds for RNA therapeutics research, thus assist in propelling the growth of this market. To boost the research activities the U.S. FDA is providing fast track designation to the RNA products, which are in the pipeline. The study suggests that the enabled technologies such as RNA interference technology (RNAi) and RNA antisense technology will dominate the market with RNAi technology getting interest from most of the participants. The development pipeline suggests that oncology segment will emerge as the largest application segment. This is largely due to the high prevalence of such diseases and limited efficiency of available therapeutics in treating such diseases. Scope of the Report MARKET BY TECHNOLOGY - Enabling technologies - Microarrays - Labeling - Purification - Linear amplification - qRT-PCR - Inhibition - Enabled technologies - RNA Interference (RNAi) technologies - Small interfering RNA (siRNA) - MicroRNA (miRNA) - RNA antisense technologies MARKET BY APPLICATION - Cardiovascular - Kidney Diseases - Oncology - Infectious diseases - Metabolic disorders - Others MARKET BY END USERS - Research - Therapeutics - Diagnosis Companies Mentioned - Alnylam Pharmaceuticals - Benitec Biopharma Limited (Australia) - Cenix BioScience GmbH (Germany) - Dicerna Pharmaceuticals - Genzyme Corporation (USA) (A Sanofi Company) - Quark Pharmaceuticals - Silence Therapeutics PLC (UK) - Sirnaomics - Tekmira Pharmaceuticals Corp. (Canada) For more information visit http://www.researchandmarkets.com/research/4c..._rna_based
DRNA: 3.68 (unch), TKMR: 10.83 (+0.58)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.27 (unch), IMMU: 2.96 (-0.01), ONCY: 0.33 (-0.02), OMED: 10.91 (+0.18), PFE: 35.36 (+0.27), INCY: 86.22 (+4.32), LLY: 79.50 (-0.07), GSK: 44.38 (-0.03), MNTA: 11.98 (-0.02), MACK: 5.19 (-0.08), SNTA: 0.34 (+0.07), INSY: 17.65 (+1.28), HALO: 10.13 (+0.03), GILD: 82.02 (+0.55), MRK: 63.44 (-0.14), ABBV: 66.00 (-0.17), NVS: 81.12 (-0.24), CELGZ: 1.26 (+0.11)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 13.58 (+0.17), PFE: 35.35 (+0.26), OMER: 11.19 (-0.07), ICPT: 168.04 (+0.97), ABBV: 66.00 (-0.17), IONS: 34.26 (+0.55), NVS: 81.13 (-0.23)
Acute Lung Injury - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 5:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mlvm2/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Altor BioScience Corporation - Apeptico Forschung und Entwicklung GmbH - Bayer AG - BioMarck Pharmaceuticals, Ltd. - Carolus Therapeutics, Inc. - CompleGen, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Histocell S.L. - Navigen Pharmaceuticals, Inc. - Noxxon Pharma AG - Quark Pharmaceuticals, Inc. - S-Evans Biosciences, Inc. - Silence Therapeutics Plc - Stemedica Cell Technologies, Inc. - Xiber Science GmbH Key Topics Covered: - Introduction - Acute Lung Injury Overview - Therapeutics Development - Pipeline Products for Acute Lung Injury - Overview - Pipeline Products for Acute Lung Injury - Comparative Analysis - Acute Lung Injury - Therapeutics under Development by Companies - Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes - Acute Lung Injury - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lung Injury - Products under Development by Companies - Acute Lung Injury - Products under Investigation by Universities/Institutes - Acute Lung Injury - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/2m...ung_injury
GSK: 44.38 (-0.03)
Silence Therapeutics Plc Industry - Product Pipeline Review - 2015
M2 - Wed Dec 23, 4:02AM CST
Acute Market Reports's, 'Silence Therapeutics plc - Product Pipeline Review - 2015', provides an overview of the Silence Therapeutics plc's pharmaceutical research and development focus.
Liver Failure Pipeline Review, H2 2015 - Analysis, Trends & Forecasts
M2 - Thu Dec 17, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/8578pm/liver_failure) has announced the addition of the "Liver Failure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Liver Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Liver Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics Companies Mentioned: - Alfact Innovation - Cell2B S.A. - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Immune Pharmaceuticals Inc. - Silence Therapeutics Plc - Ventria Bioscience For more information visit http://www.researchandmarkets.com/research/85...er_failure
CNAT: 1.97 (+0.04), IMNP: 0.38 (unch)
Acute Respiratory Distress Syndrome Pipeline Report 2015 - 12 Companies & 23 Drug Profiles
M2 - Tue Dec 15, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/ct5nmx/acute_respiratory) has announced the addition of the "Acute Respiratory Distress Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Athersys, Inc. - BioMarck Pharmaceuticals, Ltd. - Faron Pharmaceuticals Oy - FirstString Research, Inc. - GlaxoSmithKline Plc - Histocell S.L. - Myelo Therapeutics GmbH - Phylogica Limited - Serendex Pharmaceuticals A/S - Silence Therapeutics Plc - Therabron Therapeutics, Inc. Drug Profiles - ALT-836 - BIO-10901 - CG-367 - Cyndacel-M - GSK-2586881 - GSK-2862277 - interferon beta-1a - molgramostim - Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - MultiStem - Myelo-001 - Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - PYC-35 - PYC-36 - PYC-38 - PYC-98 - Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - S-1229 - SAN-101 - Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Stem Cell Therapy for Inflammatory Lung Diseases - Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome For more information visit http://www.researchandmarkets.com/research/ct...espiratory
GSK: 44.38 (-0.03), ATHX: 1.98 (unch)
Global Pulmonary Arterial Hypertension Pipeline Report H2 2015
M2 - Thu Dec 10, 10:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7nnftw/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bial - Portela & Ca, S.A. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Insmed Incorporated - Lacer, S.A. - LTT Bio-Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - miRagen Therapeutics, Inc. - Nippon Shinyaku Co., Ltd. - Novartis AG - Peloton Therapeutics, Inc. - PharmaIN Corporation - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Pulmokine, Inc. - Reata Pharmaceuticals, Inc. - Respira Therapeutics, Inc. - Sagene Pharmaceuticals, Inc. - Silence Therapeutics Plc - Sinoxa Pharma GmbH - SteadyMed Therapeutics, Inc. - Suda Ltd - Toray Industries, Inc. For more information visit http://www.researchandmarkets.com/research/7nnftw/pulmonary
CYTK: 12.27 (+0.14), INSM: 13.58 (+0.17), PSTI: 1.72 (+0.04), LLY: 79.50 (-0.07), CLSN: 1.32 (unch), ASND: 18.45 (unch), GILD: 82.02 (+0.55), ARNA: 1.68 (unch), NVS: 81.13 (-0.23)
PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis
M2 - Fri Sep 25, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nl5w7p/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report to their offering. "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, we provide an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights into the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of RNAi therapeutics. Key Questions Answered - What are the drivers of the RNAi therapy field? - Who are the leading companies involved in the development of RNAi therapies? - What are the major trends in RNAi clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the antisense/RNAi therapy field? Scope - This report provides market developments across the RNAi therapy field, including clinical trials, deals, and pipeline investments - Investment examined from both industry and financial communities - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activities - Deals examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 25 leading biotech companies developing RNAi therapeutics Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Report Scope 2.2 Companies Mentioned 2.3 Related Reports 3 Antisense RNAi Therapy Overview 3.1 What is Antisense Therapy? 3.2 The Second Era of RNAi 4 Clinical Trials 4.1 Overview 4.2 Company 4.3 Phase of Development 4.4 Therapy Area 4.5 Indication 4.6 Investigators 5 Company Analysis 5.1 Overview 5.2 Pipeline Profiles 6 Deals Landscape 6.1 Overview 6.2 Deal Type 7 Strategic Outlook 8 Appendix Companies Featured: - Alnylam Pharmaceuticals - Antisense Therapeutics - Arrowhead Research Corporation - AuraSense Therapeutics - BioMarin Pharmaceuticals - Dicerna Pharmaceuticals - Gene Signal International SA - Idera Pharmaceuticals - InDex Pharmaceuticals AB - Isarna Therapeutics GmbH - Isis Pharmaceuticals - Miragen Therapeutics - Mirna Therapeutics - Moderna Therapeutics - Mologen AG - Oncogenex Pharmaceuticals - Quark Pharmaceuticals - Regulus Therapeutics - RXi Pharmaceuticals - Sarepta Therapeutics - Silence Therapeutics Plc - Sirnaomics - Sterna Biologicals GmbH - Sylentis SA - Tekmira (Arbutus) Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/nl...armasphere
ISIS: 57.56 (-0.28), IDRA: 2.04 (+0.09), DRNA: 3.68 (unch), ARWR: 7.52 (-0.56), SRPT: 27.99 (+1.75), RGLS: 3.49 (+0.05), MIRN: 3.12 (+0.02)
Acute Lung Injury Pipeline Review, H1 2015 - 15 Companies & 37 Drug Profiles
M2 - Tue Jul 28, 9:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w2nt98/acute_lung_injury) has announced the addition of the "Acute Lung Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Apeptico Forschung und Entwicklung GmbH - BioMarck Pharmaceuticals, Ltd. - Carolus Therapeutics, Inc. - CompleGen, Inc. - FirstString Research, Inc. - GlaxoSmithKline Plc - Histocell S.L. - Navigen Pharmaceuticals, Inc. - Noxxon Pharma AG - S-Evans Biosciences, Inc. - Silence Therapeutics Plc - Stemedica Cell Technologies, Inc. - Therametrics holding AG - Xiber Science GmbH Drug Profiles - ALT-836 - AP-301 - Atu-111 - Atu-112 - BC-1215 - BIO-10901 - CGX-1037 - CT-2009 - DasKloster-0141-01 - DasKloster-1000-04 - Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - GSK-2586881 - GSK-2862277 - HC-016 - LTI-02 - Mesenchymal Stem Cells - MG-53 - Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - NOXD-19 - P- BEFizumab - Peptide to Activate PAI-1 for Acute Lung Injury - Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - S-1229 - Small Molecules for Inflammatory Diseases and Sepsis - Small Molecules to Inhibit Arf6 for Multiple Diseases - Stem Cell Therapy for Acute Lung Injury - Stem Cell Therapy for Inflammatory Lung Diseases - Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Stromal Cell Therapy for Acute Lung Injury - Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury For more information visit http://www.researchandmarkets.com/research/w2...ung_injury
GSK: 44.38 (-0.03)
Silence Therapeutics plc - Product Pipeline Review - 2014
M2 - Wed Jun 17, 4:39AM CDT
Global Sepsis Pipeline Review 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch9d7/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adrenomed AG - Altor BioScience Corporation - Am-Pharma B.V. - Arch Biopartners, Inc. - Asahi Kasei Pharma Corp. - Baxter International Inc. - Biomedica Management Corporation - Chiesi Farmaceutici SpA - Chiome Bioscience, Inc. - Cilian AG - Cognosci, Inc. - Diomune S.L - Endacea, Inc. - Evec, Inc. - Huons Co., Ltd. - Immune Response BioPharma, Inc. - ImmunNovative Developments SL - InflaRx GmbH - Integrated BioTherapeutics, Inc. - ISU ABXIS Co.,Ltd. - Lead Discovery Center GmbH - MSM Protein Technologies, Inc. - Navigen Pharmaceuticals, Inc. - Novadiscovery SAS - Noxxon Pharma AG - Ocata Therapeutics, Inc. - OncoImmune, Inc. - Opsona Therapeutics Ltd. - ProThera Biologics, LLC. - Silence Therapeutics plc - Stemedica Cell Technologies, Inc. - Syntiron LLC - Takeda Pharmaceutical Company Limited - TiGenix NV - XImmune AB For more information visit http://www.researchandmarkets.com/research/gc...s_pipeline
OCAT: 8.47 (+0.01), BAX: 47.75 (-0.23), ACH: 9.15 (+0.10)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 82.02 (+0.55), PFE: 35.36 (+0.27), GALT: 2.01 (+0.02), FGEN: 19.43 (+0.32), CELGZ: 1.26 (+0.11)
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 82.02 (+0.55), ICPT: 168.04 (+0.97), TBRA: 4.76 (-0.09), CELGZ: 1.26 (+0.11)
Ischemia Reperfusion Injury - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6pp4ft/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Pharming Group N.V. - BioLineRx, Ltd. - Silence Therapeutics plc - Proteo, Inc. - Scynexis, Inc. - Prolong Pharmaceuticals - Trophos SA - Curatis Pharma GmbH - Alligator Bioscience AB - Opsona Therapeutics Ltd. - PledPharma AB - Zealand Pharma A/S - Omeros Corporation - Bolder Biotechnology, Inc. - Adienne S.r.l. - Genextra S.p.a. - KAEL-GemVax Co., Ltd. - Ischemix - APT Therapeutics, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/6pp4ft/ischemia
OMER: 11.19 (-0.07)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 2.96 (-0.01), AMGN: 174.04 (-0.36), RGLS: 3.49 (+0.05), LLY: 79.50 (-0.07), GSK: 44.38 (-0.03), PVCT: 0.25 (unch), CANF: 2.41 (+0.04), DCTH: 3.99 (-0.05), NVS: 81.12 (-0.24), XLRN: 31.66 (+0.75)
Global RNA Based Therapeutics Market 2014-2020: Market to Grow at CAGR of 28% and Reach $1.2 Billion in 2020
M2 - Wed Oct 22, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4cwd5m/global_rna_based) has announced the addition of the "Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The RNA Based Therapeutics Market would reach $1.2 billion by 2020 registering a CAGR of 28.4% during 2014 - 2020 Due to its ability to render targeted solutions for chronic diseases such as cancer, AIDS, rare genetic disorders, and certain cardiovascular conditions, RNA based therapeutics is expected to significantly impact the global pharmaceutical industry. The large scale funding from public and private sector, growing interest of pharmaceuticals and biotech giants for developing novel delivery technology, and anticipated saving in healthcare expenditure are propelling the growth of RNA therapeutics market. Moreover, the platform technologies such as RNAi and antisense have enabled researchers to accelerate their research activities by defining gene sequences for chronic diseases. Companies have widened the research focus on RNA based drug as well, which has fueled the growth of the overall RNA therapeutics market.Pharmaceutical companies have identified the RNA therapeutics for variety of chronic diseases and are also exploring the potential of RNA technology for diagnostic purposes. The RNA based therapeutics market, in the near future is likely to witness a substantial level of momentum due to government funding and programs aimed at commercialization of these drugs. The government of United States, through its National Institute of Health (NIH), provides funds for RNA therapeutics research, thus assist in propelling the growth of this market. To boost the research activities the U.S. FDA is providing fast track designation to the RNA products, which are in the pipeline. The study suggests that the enabled technologies such as RNA interference technology (RNAi) and RNA antisense technology will dominate the market with RNAi technology getting interest from most of the participants. The development pipeline suggests that oncology segment will emerge as the largest application segment. This is largely due to the high prevalence of such diseases and limited efficiency of available therapeutics in treating such diseases. Scope of the Report MARKET BY TECHNOLOGY - Enabling technologies - Microarrays - Labeling - Purification - Linear amplification - qRT-PCR - Inhibition - Enabled technologies - RNA Interference (RNAi) technologies - Small interfering RNA (siRNA) - MicroRNA (miRNA) - RNA antisense technologies MARKET BY APPLICATION - Cardiovascular - Kidney Diseases - Oncology - Infectious diseases - Metabolic disorders - Others MARKET BY END USERS - Research - Therapeutics - Diagnosis Companies Mentioned - Alnylam Pharmaceuticals - Benitec Biopharma Limited (Australia) - Cenix BioScience GmbH (Germany) - Dicerna Pharmaceuticals - Genzyme Corporation (USA) (A Sanofi Company) - Quark Pharmaceuticals - Silence Therapeutics PLC (UK) - Sirnaomics - Tekmira Pharmaceuticals Corp. (Canada) For more information visit http://www.researchandmarkets.com/research/4c..._rna_based
DRNA: 3.68 (unch), TKMR: 10.83 (+0.58)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.27 (unch), IMMU: 2.96 (-0.01), ONCY: 0.33 (-0.02), OMED: 10.91 (+0.18), PFE: 35.36 (+0.27), INCY: 86.22 (+4.32), LLY: 79.50 (-0.07), GSK: 44.38 (-0.03), MNTA: 11.98 (-0.02), MACK: 5.19 (-0.08), SNTA: 0.34 (+0.07), INSY: 17.65 (+1.28), HALO: 10.13 (+0.03), GILD: 82.02 (+0.55), MRK: 63.44 (-0.14), ABBV: 66.00 (-0.17), NVS: 81.12 (-0.24), CELGZ: 1.26 (+0.11)
